Shimoni, Yakhin, and Xiu-Fang Liu. Gender differences in ANG II levels and action on multiple K ϩ current modulation pathways in diabetic rats. Am J Physiol Heart Circ Physiol 287: H311-H319, 2004. First published April 15, 2004; 10 .1152/ajpheart.01212.2003.-Gender differences were studied in ventricular myocytes from insulindeficient (Type 1) diabetic rats. Cells were obtained by enzymatic dispersion of hearts from control male and female rats and from rats made diabetic with streptozotocin (100 mg/kg) 7-14 days before experiments. ANG II content, measured by ELISA, was augmented in diabetic males but unaltered in diabetic females. In diabetic ovariectomized females, ANG II levels were augmented as in males. ANG II affects multiple cellular pathways including activation of protein kinase C (PKC) and several tyrosine kinases as well as inhibition of protein kinase A (PKA). The involvement of these pathways in modulating outward K ϩ currents was studied. Transient and sustained outward K ϩ currents were measured using the whole cell voltageclamp method. In males, these currents are attenuated under diabetic conditions but are augmented by the ANG II-converting enzyme inhibitor quinapril. Activation of PKA by 8-bromo-cAMP enhanced both K ϩ currents in cells from diabetic males. The augmentation of these currents by quinapril was blocked when PKA inhibition was maintained with the Rp isomer of 3Ј,5Ј-cyclic monophosphorothioate. Inhibition of tyrosine kinases by genistein also augmented K ϩ currents in cells from diabetic males. Action potentials were abbreviated by 8-bromo-cAMP and genistein. However, both genistein and 8-bromo-cAMP had no effect on K ϩ currents in cells from diabetic females. In cells from ovariectomized diabetic females, 8-bromocAMP and genistein enhanced these K ϩ currents as in males. Inhibition of PKC augmented the transient and sustained K ϩ currents in cells from diabetic males and females. A contribution of non-ANG II-dependent activation of PKC is suggested. These results describe some of the mechanisms that may underlie gender-specific differences in the development of cardiac disease and arrhythmias. angiotensin II; streptozotocin; diabetes mellitus; cardiovascular THE INCIDENCE OF DIABETES MELLITUS is rapidly increasing (39) . Despite improved treatment, cardiovascular complications continue to develop and are presently the leading cause of diabetes-related mortality (21) . The mechanical and electrical activities of the heart are altered (8, 30) , and susceptibility to arrhythmias is increased (18, 28) . One possible mechanism underlying diabetes-related arrhythmogenesis is the attenuation of repolarizing K ϩ currents and the prolongation of the ventricular action potential (19) . This destabilizes repolarization and leads to increased dispersion and prolongation of QT intervals in the electrocardiograms of diabetic patients (8, 16, 27) . Such changes are established life-threatening risk factors (36) .
Diabetes has been shown to induce activation of a cardiac renin-angiotensin system (9, 29) . In earlier work (32), we suggested that an autocrine/paracrine action of ANG II is partially responsible for the attenuation of repolarizing K ϩ currents and for action potential prolongation in cardiomyocytes isolated from insulin-deficient (Type 1) diabetic rats and from Type 2 diabetic db/db mice. In vitro inhibition of the angiotensin-converting enzyme (ACE) or blockade of ANG II receptors produced augmentation of K ϩ currents due to enhanced synthesis of channel proteins (34) .
More recently, we determined that there is a striking gender dependence associated with this effect (35) . In myocytes from streptozotocin (STZ)-treated diabetic females, K ϩ currents were not affected by ACE inhibition. Estrogen, which is known to interact with the angiotensin pathway (6, 11) , was shown to play a role in the gender-selective effects of ACE inhibition on K ϩ currents. Thus in ovariectomized (Ovx) diabetic female rats that have greatly reduced estrogen levels, ACE inhibition augmented these K ϩ currents as in diabetic males. In addition, in vitro incubation with 17␤-estradiol was found to augment these currents, presumably due to suppression of the reninangiotensin system. However, this effect was inhibited by addition of ANG II (35) .
In our previous studies (34, 35) , the effects of ANG II were inferred indirectly through these pharmacological interventions.
In the present study, we set out to directly measure ANG II content in myocytes from control and diabetic rats and to determine whether gender differences could be established. In addition, we aimed to determine some of the consequences of genderselective activation of angiotensin-dependent pathways.
ANG II has a large number of diverse cellular effects (37) . These involve several distinct pathways utilizing different second-messenger systems. In cardiac cells, ANG II activates protein kinase C (PKC; Ref. 20) as well as a variety of tyrosine kinases (12, 13) . ANG II also inhibits the action of protein kinase A (PKA; Ref.
3). The ANG II-dependent activation of PKC and inhibition of PKA have been linked to activation or inhibition of several ionic channels (1, 14, 24) .
The present study addressed several issues that are of great interest for understanding pathological mechanisms that are activated in the setting of diabetes. The questions addressed were the following: 1) Are there gender differences in ANG II content in cardiac myocytes in diabetes? 2) Are (some of the) ANG II-activated transduction pathways linked to the attenuation of K ϩ currents in diabetes? 3) Are there differences between the actions of these pathways in myocytes from control and diabetic rats? and 4) Are there gender differences in the actions of these pathways? The results presented here provide affirmative answers to these questions.
METHODS
This study, approved by the University of Calgary Animal Care Committee, conforms to the Guide for Care and Use of Laboratory Animals published by the US National Institutes of Health.
Animals. The study was performed on male and female SpragueDawley rats (body wt, 220 -300 g) that were randomly separated into control and diabetic groups. Insulin-deficient diabetes was induced with a single injection of STZ (100 mg/kg iv) given 7-14 days before isolation of ventricular cells. The diabetic state (elevated glucose and reduced insulin in plasma samples) was confirmed in our earlier studies (e.g., Ref. 33) . Another group of Ovx female rats was also used. These were made diabetic with STZ 2-3 wk after ovariectomy, and cells were isolated 7-14 days after STZ injection.
Cell isolation. Single ventricular myocytes were obtained by enzymatic dispersion. Rats were anesthetized by CO 2 inhalation and then killed by cervical dislocation. The hearts were removed and the aortas cannulated on a Langendorff apparatus for retrograde coronary perfusion. The hearts were perfused for 3-5 min (at 37°C, bubbled with a 95% O 2-5% CO2 mixture) with a control solution that consisted of (in mM) 121 NaCl, 5.4 KCl, 2.8 sodium acetate, 1 MgSO4, 5 Na 2HPO4, 24 NaHCO3, 5 glucose, and 1 CaCl2 (brought to a pH of 7.4 with NaOH). The solution was switched to a calcium-free solution (other constituents were unchanged). After 10 min, this was changed to the same basic solution that also contained 0.015 mg/ml collagenase (Yakult Honsha), 0.0075 mg/ml protease (Sigma type XIV), 20 mM taurine, and 40 M CaCl 2. After 8 min, the free wall of the right ventricle was cut into small chunks, which were further incubated in a shaker bath (at 37°C) in a solution that contained 0.3 mg/ml collagenase, 0.15 mg/ml protease, 20 mM taurine, and 10 mg/ml albumin. Aliquots of cells were removed over the next 10 -20 min and stored at room temperature in a solution that contained no enzymes, 20 mM taurine, 5 mg/ml albumin, and 0.1 mM CaCl 2. Cells were divided into groups that consisted of untreated cells or cells incubated with various drugs. On each experimental day, treated cells were compared with untreated cells. This allowed for variations in the degree of diabetic conditions in different rats. Results were pooled from different days and are given as means Ϯ SE.
Current recording. Aliquots of cells were placed on the stage of an inverted microscope and perfused (at 21-22°C) with a solution that contained (in mM) 150 NaCl, 5.4 KCl, 1 CaCl 2, 1 MgCl2, 5 HEPES, and 5 glucose (brought to a pH of 7.4 with NaOH); 0.3 mM CdCl2 was then added to block L-type calcium currents.
The whole cell voltage-clamp method was used to record currents, which were elicited by 500-ms pulses to membrane potentials ranging from Ϫ110 to ϩ50 mV. Recording pipettes (2-3 M⍀ resistance) contained filling solutions of (in mM) 120 potassium aspartate, 30 KCl, 4 Na 2-ATP, 10 HEPES, 10 EGTA, 1 CaCl2, and 1 MgCl2. Peak outward current (Ipeak) and sustained outward current (Isus, measured at the end of the voltage step), the key determinants of action potential repolarization and duration, were measured and compared.
Currents were digitized at 2 kHz and normalized to cell size by dividing current amplitude by cell capacitance (measured by integrating current traces obtained in response to 5-mV steps from Ϫ80 mV). Results are thus presented as current density.
Cell capacitance. Changes in current density may reflect changes in cell size, particularly under diabetic conditions, where ANG II may have hypertrophic effects. Insulin deficiency may also act to reduce cell size. However, measurements of cell capacitance, which is an index of cell size, showed (by ANOVA) no significant differences (P Ͼ 0.25) between any of the groups studied. Table 1 shows these values.
Action potentials were recorded using the current-clamp mode. In these experiments, CdCl 2 was omitted from the bathing solution.
ANG II content. ANG II was measured in isolated myocytes by ELISA using a kit from Peninsula Laboratories. Cell extracts (4 -6 million rod-shaped striated cells per rat) were first run through C 18 Sep columns. Six-point standard curves were obtained for each trial using known concentrations with optical densities plotted against (log) concentrations. Experimental samples, tested in triplicate, fell within the linear ranges of these curves. ANG II levels were normalized for protein content, measured in the same samples using a bicinchoninic acid protein assay kit (Pierce). The values obtained were very similar to those reported by Fiordaliso et al. (9) .
Statistics. Mean values were compared using Student's t-test or ANOVA with Student-Newman-Keuls multiple comparisons test. Differences with P values Ͻ0.05 were considered significant.
RESULTS
The first set of experiments measured ANG II content in isolated ventricular myocytes using ELISA. Fiordaliso et al. (9) had previously shown that ANG II content was elevated in myocytes from male STZ-treated diabetic rats. We confirmed this and showed a significant (P Ͻ 0.01 by ANOVA) elevation of ANG II content. We subsequently measured ANG II content in cells from female STZ-treated diabetic rats. Our earlier work showed gender-selective effects in which the ACE inhibitor quinapril augmented K ϩ currents only in cells from diabetic males (35) . This suggested that the renin-angiotensin system was not activated in diabetic females. In the present work, we found that ANG II content was indeed not different in control and STZ-treated diabetic females. Our earlier work also showed that ACE inhibition does augment K ϩ currents in cells from Ovx diabetic females (35) . This suggested that estrogen plays a major role in suppressing ANG II activation. In assays performed with cells from Ovx diabetic females, we found that ANG II content was significantly (P Ͻ 0.001) elevated (compared with control and diabetic females) and comparable to levels found in diabetic males. These results are shown in Fig. 1 .
The baseline ANG II content was found to be lower in control females compared with control males (not quite significant for this small sample). This difference may be due to the fact that in males there is a baseline ANG II production level that is augmented under diabetic conditions. This baseline production may be suppressed in control females. We therefore investigated whether addition of quinapril to isolated myocytes from control rats produced gender-selective effects.
Incubation of cells from male rats with 1 M quinapril for 5-9 h did not alter I peak but significantly augmented I sus . Mean Values are means Ϯ SE; n, no. of myocytes (in parentheses). Ovx, ovariectomized.
I peak densities (at ϩ50 mV) were 22.8 Ϯ 1.3 (n ϭ 24) and 20.1 Ϯ 1.5 pA/pF (n ϭ 21) in the absence of and after incubation with quinapril, respectively (P Ͼ 0.05). The corresponding values for I sus were 6.2 Ϯ 0.3 and 7.3 Ϯ 0.3 pA/pF (P Ͻ 0.02). In cells from control females, quinapril did not alter either current (P Ͼ 0.05). I peak densities were 20.1 Ϯ 1.2 (n ϭ 24) and 23.1 Ϯ 1.1 pA/pF (n ϭ 20). The values for I sus in these groups were 7.9 Ϯ 0.3 and 8.0 Ϯ 0.4 pA/pF. This result suggests the presence of a baseline production level of ANG II (leading to some I sus suppression) in control males but not in females. Diabetes enhances the production of ANG II only in males, which leads to suppression of I peak and I sus . We subsequently proceeded to investigate whether some of the second-messenger systems affected by ANG II are involved in suppression of these currents.
The first set of experiments was based on work showing the involvement of ANG II-linked suppression of PKA (14) . The hypothesis was that if PKA inhibition by ANG II were linked to current attenuation, it would be possible to augment these currents by PKA activation. Cells from male STZ-treated diabetic rats were incubated with the cell-permeable PKA activator 8-bromo-cAMP (100 M) for 5-9 h. This produced significant augmentation of both I peak and I sus . At ϩ50 mV, I peak densities were 13.3 Ϯ 0.9 and 16.7 Ϯ 1.3 pA/pF in the absence (n ϭ 39) or presence (n ϭ 28) of 8-bromo-cAMP (P Ͻ 0.03). The corresponding values for I sus were 4.5 Ϯ 0.2 and 7.1 Ϯ 0.5 pA/pF (P Ͻ 0.0001). Sample current traces and the mean current densities are shown in Fig. 2 .
Cells from control (nondiabetic) male rats were also incubated with 100 M 8-bromo-cAMP. This was found to have no effect on either I peak or I sus . Mean I peak densities in these experiments were 24.7 Ϯ 1. This result suggests that PKA is indeed suppressed in cells from diabetic rats (see DISCUSSION) . However, this is not necessarily linked to activation of the renin-angiotensin system. Fig. 1 . ANG II content in isolated myocytes. ELISA was used to compare ANG II in myocyte extracts from male (A) and female (B) control and diabetic rats. Augmentation of ANG II content occurs only in males. As shown, ANG II content in cells from ovariectomized (Ovx) diabetic female rats is similar to that in diabetic males. ANG II content was measured in triplicate for each sample and normalized for protein content; n ϭ no. of rats, shown in parentheses below each bar. *P Ͻ 0.05. Fig. 2 . A: effects of protein kinase A (PKA) activation by 8-bromo-cAMP (8 Br-cAMP). Current traces (obtained in response to 500-ms pulses to potentials ranging from Ϫ10 to ϩ50 mV) in cells from diabetic male rats in the absence of 8-bromocAMP and following 6 h of incubation with 8-bromo-cAMP (100 M). B: mean (Ϯ SE) current densities (at ϩ50 mV) for peak outward current (Ipeak) and sustained outward current (Isus) in the absence of or 5-9 h after addition of 8-bromo-cAMP. *P Ͻ 0.05; **P Ͻ 0.005.
To establish such a link, an additional set of experiments was performed. The ACE inhibitor quinapril was found earlier to augment I peak and I sus (32, 35) . We hypothesized that if PKA suppression were one of the links between ANG II activation and current attenuation, then maintaining PKA suppression in the presence of quinapril may prevent current augmentation. To test this, cells from diabetic rats were exposed to quinapril in the absence or presence of the cell-permeable PKA inhibitor Rp-CAMPS (100 M), which is the Rp isomer of 3Ј,5Ј-cyclic monophosphorothioate. Maintained PKA suppression was found to block the augmentation of both I peak and I sus by quinapril. These results are shown in Fig. 3 . Figure 3A shows sample current traces, whereas Fig. 3B shows current-voltage relationships in the absence or presence of quinapril, and with quinapril and Rp-CAMPS. ANOVA analysis showed that current augmentation by quinapril (for I peak and I sus ) was significant at membrane potentials ranging from Ϫ30 to ϩ50 mV, whereas reduction of the effect of quinapril by Rp-CAMPS was significant between Ϫ10 and ϩ50 mV.
We subsequently tested whether tyrosine kinases, which are another major target of ANG II activation, are also involved in the modulation of I peak and I sus . There are multiple types of tyrosine kinases with relatively selective inhibitors (37) . However, the subtypes of tyrosine kinases that link ANG II action to changes in currents have not yet been elucidated. We therefore used genistein, which is a nonspecific inhibitor of tyrosine kinases (2) . An advantage to using genistein is that the inactive analog genistin (26) can be used as a control for verifying tyrosine kinase involvement. Our hypothesis was that if activation of tyrosine kinases by ANG II were partly responsible for K ϩ current attenuation, then inhibition by genistein would partly reverse this effect and augment current magnitudes. A similar rationale was used previously in experiments in which inhibition of PKC (presumably activated by ANG II) augmented both I peak and I sus (34) .
In this set of experiments, cells from male STZ-treated diabetic rats were incubated with 100 M genistein for 5-9 h. This produced significant augmentation of both I peak and I sus as shown in Fig. 4 . At ϩ50 mV, I peak density was increased from 11.3 Ϯ 0.7 (n ϭ 21) to 17.0 Ϯ 1.0 pA/pF (n ϭ 18; P Ͻ 0.001), whereas I sus was increased from 4.8 Ϯ 0.2 to 5.7 Ϯ 0.3 pA/pF (P Ͻ 0.025). When cells from diabetic rats were exposed to the inactive analog genistin (100 M), there was no effect on either current. I peak densities at ϩ50 mV were 18.6 Ϯ 1.3 and 18.8 Ϯ 1.5 pA/pF in the absence (n ϭ 22) and presence (n ϭ 21) of genistin, respectively. The corresponding values for I sus were 4.5 Ϯ 0.2 and 4.9 Ϯ 0.2 pA/pF (P Ͼ 0.05). An additional set of experiments used myocytes from control rats. Incubation of these cells with genistein (100 M) also had no effects on I peak or I sus , presumably because tyrosine kinases are not sufficiently activated in control conditions to affect K ϩ currents (see discussion).
These results suggest that under diabetic conditions, an increase in ANG II activates tyrosine kinases, which, in turn, attenuate I peak and I sus . The present results, in combination with our earlier work relating to PKC activation by ANG II (34) , suggest that in the setting of diabetes the increased levels of ANG II activate or inhibit several pathways. These pathways, mediated by PKC, PKA, and tyrosine kinases, are also linked to attenuation of ventricular K ϩ currents and action potential prolongation.
In female diabetic rats, however, ANG II levels are unchanged (see Fig. 1 ), and ACE inhibition has no effect on I peak and I sus in females (35) . It was therefore hypothesized that changes in currents due to ANG II-dependent effects on PKC, tyrosine kinases, and PKA would be absent in females.
The changes in currents described in Figs. 1-4 were relatively small. However, we have shown previously (32) that changes of this magnitude (for example, after addition of the ACE inhibitor quinapril) are sufficient to alter action potential Fig. 3 . Effects of PKA inhibition on augmentation of currents by the ANG II-converting enzyme inhibitor quinapril. A: current traces (same protocol as Fig. 2 ) in cells obtained from a male diabetic rat in the absence of drugs, after 7-h incubation in 1 M quinapril, or after 6-h incubation in quinapril and 100 M Rp-CAMPS (Rp isomer of 3Ј,5Ј-cyclic monophosphorothioate), which is a PKA inhibitor that was added 1 h before quinapril. B: current-voltage relationships obtained for the same three conditions. Augmentation of both Ipeak and Isus by quinapril is significantly attenuated by Rp-CAMPS.
duration (see Fig. 3 ). In the present experiments, we also measured action potential durations in the absence of or after 5-7 h of incubation in either 8-bromo-cAMP or genistein. The increase in K ϩ currents by either of these compounds was found to significantly abbreviate action potential duration measured at Ϫ60 mV. The mean values were 55.6 Ϯ 5.7 (n ϭ 20), 33.2 Ϯ 1.8 (n ϭ 14; P Ͻ 0.005), and 36.3 Ϯ 3.9 (n ϭ 9; P Ͻ 0.04) ms in the absence of drug, with 100 M 8-bromo-cAMP, or with 100 M genistein, respectively. These results are shown in Fig. 5 .
The following experiments examined the involvement of these kinases in the modulation of I peak and I sus in cells from female STZ-treated diabetic rats. In the first set of experiments, cells from female STZ-treated diabetic rats were incubated for 5-9 h with 8-bromo-cAMP (100 M). In striking contrast to cells from males, there was indeed no effect on either I peak or I sus . Mean I peak densities at ϩ50 mV in the absence and presence of 8-bromo-cAMP were 13.3 Ϯ 0.8 (n ϭ 30) and 14.2 Ϯ 1.2 pA/pF (n ϭ 20; P Ͼ 0.05), respectively. The corresponding values for I sus were 4.7 Ϯ 0.2 and 5.1 Ϯ 0.4 pA/pF (P Ͼ 0.05). These results are shown in Fig. 6 . The experiments performed on males with the PKA inhibitor Rp-CAMPS could not be repeated in cells from females, because the ACE inhibitor quinapril is without effect in these cells (35) .
Subsequently, cells from female STZ-treated diabetic rats were exposed to 100 M genistein for 5-9 h. Again, in marked contrast to the augmentation of I peak and I sus measured in cells from males, there were no changes in either current. In this group of cells, the mean densities of I peak at ϩ50 mV in the absence or presence of genistein were 13.8 Ϯ 1.0 (n ϭ 30) and 15.2 Ϯ 1.5 pA/pF (n ϭ 21), respectively (P Ͼ 0.05). The corresponding values for I sus were 4.3 Ϯ 0.6 and 4.8 Ϯ 0.3 pA/pF (P Ͼ 0.05). These results are shown in Fig. 7 .
Finally, the involvement of PKC was also investigated. In earlier work (34), we found that incubation of cells from diabetic males with the PKC inhibitor bis-indolylmaleimide augmented both I peak and I sus . In the present study, cells from female diabetic rats were also incubated with bis-indolylmaleimide (100 nM). In contrast to the lack of effect of genistein and 8-bromo-cAMP, PKC inhibition significantly augmented Fig. 4 . Effects of tyrosine kinase inhibition on K ϩ currents in cells from diabetic rats. A: current traces (same protocol as above) obtained in the absence of or after 6.5-h incubation in 100 M genistein. B: mean current densities at ϩ50 mV for Ipeak and Isus in the absence of or after 5-9 h of incubation in 100 M genistein. Significant augmentation of both currents was attributed to tyrosine kinase inhibition (reversing tyrosine kinase activation by ANG II) because the inactive analog genistin was without effect (not shown). *P Ͻ 0.05; **P Ͻ 0.005. both I peak and I sus as in cells from diabetic males. This result is shown in Fig. 8 . Peak currents were significantly augmented (P Ͻ 0.001 to P Ͻ 0.05) at membrane potentials ranging from Ϫ40 to ϩ50 mV. I sus was significantly augmented (P Ͻ 0.001) between Ϫ50 and ϩ50 mV.
These results suggest that PKC may be activated in diabetic females by an ANG II-independent mechanism (see discussion). As in males, PKC activation contributes to K ϩ current attenuation in diabetic females. However, earlier work (35) showed the attenuation of K ϩ currents to be smaller in diabetic females than in males. The augmentation of these K ϩ currents by PKC inhibition in the present experiments is also smaller in females than in males. This was assessed as follows: individual current amplitudes obtained after PKC inhibition were divided by the mean current density obtained in untreated cells (no PKC inhibition). This gave a group of ratios (indicating the degree of current augmentation) for cells from males and females. Thus for I peak , the mean ratios for augmentation by PKC inhibition were 1.25 Ϯ 0.06 in males (n ϭ 36) and 1.10 Ϯ 0.07 in females (n ϭ 37) with the difference just short of being significant (0.07 Ͻ P Ͻ 0.08). For I sus augmentation, the ratios were 1.45 Ϯ 0.07 in males and 1.25 Ϯ 0.06 in males and females, respectively (P Ͻ 0.05). The final experiments examined whether the gender differences in the linkage between PKA inhibition, tyrosine kinase activation, and current attenuation could be attributed to estrogen. Our earlier work suggested that estrogen, which is known to suppress the angiotensin pathway (11, 23) , accounts for the gender differences in autocrine modulation of K ϩ currents. Thus ACE inhibition augmented I peak and I sus in diabetic Ovx rats in contrast to the lack of effect in diabetic (non-Ovx) females. In the present experiments, Ovx female rats were made diabetic by STZ treatment 2-3 wk after removal of the ovaries. Cells were isolated 7-14 days later, and similar protocols to those described were repeated.
The first set of experiments demonstrated that 8-bromocAMP (100 M for 5-9 h) significantly augmented I peak and I sus as in males. In this group, I peak at ϩ50 mV was increased from 16.6 Ϯ 1.2 (n ϭ 21) to 24.0 Ϯ 1.9 pA/pF (n ϭ 13; P Ͻ 0.002). I sus was increased from 5.7 Ϯ 0.3 to 7.6 Ϯ 0.5 pA/pF (P Ͻ 0.004). This result is shown in Fig. 9 . Fig. 8 . Effects of the protein kinase C (PKC) inhibitor bisindolylmaleimide (bis-indol) in cells from STZ-treated diabetic females. A: sample current traces in the absence of drugs or after 6-h incubation with 100 nM PKC inhibitor. B: current-voltage relationships (Ipeak, left; Isus, right). PKC inhibition augmented both currents with significant differences obtained at potentials ranging from 0 to ϩ50 mV. Fig. 9 . Effects of 8-bromo-cAMP on outward currents in cells from Ovx diabetic female rats. A: sample current traces in the absence of drug and after 7-h incubation in 100 M 8-bromo-cAMP. B: mean current densities at ϩ50 mV in the absence of or after 5-9 h of incubation with 8-bromo-cAMP. Both currents are significantly augmented as in diabetic males but unlike non-Ovx diabetic females. **P Ͻ 0.005.
In a second set of experiments, cells from Ovx diabetic females were incubated with 100 M genistein for 5-9 h. As in males but unlike in normal females, this produced augmentation of I peak and I sus . In this group, I peak (at ϩ50 mV) was augmented from 17.0 Ϯ 1.0 (n ϭ 29) to 20.3 Ϯ 1.3 pA/pF (n ϭ 17; 0.05 Ͻ P Ͻ 0.055). I sus was augmented from 5.4 Ϯ 0.2 to 7.3 Ϯ 0.5 pA/pF (P Ͻ 0.0002). Figure 10 shows a comparison of the effects of genistein on I sus in male, female, and Ovx diabetic rats.
DISCUSSION
The results presented describe several novel findings. This work is the first to establish gender differences in the content of ANG II, a potent autocrine agent, in the setting of cardiac pathophysiology. In addition, we show that ANG II has multiple effects on transient and sustained repolarizing currents in cardiac myocytes from diabetic male rats with several secondmessenger systems linking ANG II activation to the attenuation of these currents. Finally, we demonstrate that some of these pathways are not operative in cells from diabetic females but are reactivated after ovariectomy.
Earlier work (3, 14) showed inhibition of the PKA pathway by ANG II. The present results show that under diabetic conditions, activation of PKA by 8-bromo-cAMP augments I peak and I sus in cells from males but not females (see Figs. 2  and 6 ). This suggests that PKA is inhibited in males but not in females, presumably due to the gender differences in ANG II elevation (see Fig. 1 ). Support for the involvement of ANG II in mediating PKA involvement was obtained by experiments showing that the augmentation of currents by the ACE inhibitor quinapril was blocked when PKA inhibition was maintained (see Fig. 3 ). That 8-bromo-cAMP was without effect on either current in cells from control males also suggests that only after ANG II levels rise is there inhibition of PKA, which contributes to current attenuation.
The inhibition of tyrosine kinases by genistein also augmented K ϩ currents in cells from diabetic males but not females (see Figs. 4 and 7) . This is in concordance with the known activation of tyrosine kinases by ANG II (37), which would not occur in females in the absence of ANG II elevation. Again, the lack of effect of genistein on I peak and I sus in cells from control males supports the suggestion that tyrosine kinases are activated only after ANG II is elevated under diabetic conditions. This link between tyrosine kinases and K ϩ currents in diabetes has not been reported before. It is possible that the high concentration of genistein used led to effects on other kinases. However, no effects on currents were found in control myocytes, which indicates that the drug target had changed in the diabetic state. In addition, there are gender differences in the effects of genistein on diabetic cells that indicate differences in the target of genistein action.
The activation of PKC by ANG II has been amply demonstrated before (20, 37) . A link between PKC activation and cardiac K ϩ current inhibition has also been shown (22, 31) . Interestingly, the effects of the PKC inhibitor on I peak and I sus were still present (see Fig. 8 ) in cells from diabetic females (although to a smaller degree than in males). This suggests that some PKC activation occurs in diabetic females independently of ANG II. This PKC activation leads to current attenuation as it does in males. An alternative mechanism for PKC activation could be the de novo synthesis of the PKC activator diacylglycerol, which occurs during hyperglycemic conditions (15, 38) . The larger augmentation of I peak and I sus by PKC inhibition in males may be due to a larger activation of PKC (and enhanced attenuation of currents). This would reflect the combined contribution of ANG II and de novo synthesis of diacylglycerol in diabetic males with only the latter mechanism present in females.
The effects described here, whereby K ϩ currents are augmented, presumably reflect the synthesis of new channel proteins. We showed this in earlier work (34) using Western blotting with antibodies directed against Kv4.2 and Kv1.2, which (partially) underlie I peak and I sus . In that work, ACE inhibition increased (after Ͼ5 h) channel-protein abundance, which suggests that the increase in ANG II associated with the diabetic state inhibits channel-protein synthesis. This will attenuate both transient and sustained K ϩ currents. In the present work, it is hypothesized that activation of PKA or inhibition of tyrosine kinases also blocks the action of ANG II and thereby allows enhanced channel synthesis rather than direct modulation of the currents.
The suppressing role of estrogen on the renin-angiotensin system has been implicated in previous studies (6, 11, 23) . Our results suggest that estrogen plays a major role in preventing K ϩ current changes as well, because the activation of PKA and the inhibition of tyrosine kinases by genistein augmented I peak and I sus only in Ovx females (see Figs. 9 and 10) .
The results presented here illustrate the presence of important gender differences in an autocrine regulation of major repolarizing currents in cardiac cells. These differences may underlie the differential propensity for development of some cardiac arrhythmias in males and females (4, 17, 25) . ANG II is increasingly recognized as a central mediator of cardiac pathophysiology (7) . Upregulation of the renin-angiotensin system occurs during heart failure as well as during diabetes (5) and has been shown to accelerate cell death in human Fig. 10 . Comparison of the effects of genistein on Isus in diabetic males (left), females (middle), and Ovx females (right). Mean current densities (at ϩ50 mV) are shown in the absence of drugs or after 5-9 h of incubation in 100 M genistein. Isus is significantly augmented in males and Ovx females but not in diabetic females. The results suggest that (in females) estrogen prevents ANG II activation of tyrosine kinases. Thus no attenuation of currents occurs, so that current augmentation by genistein is also absent. *P Ͻ 0.05; **P Ͻ 0.005; n.s., not significant. diabetes (10) . Our earlier work (32, 34) showed that blocking ANG II receptors also enhances K ϩ currents as does the inhibition of ANG II formation. In addition, the enhancement of current magnitude by the receptor blocker saralasin was shown to be absent when PKC translocation was prevented (34) . The present work shows gender-specific differences in both ANG II formation and in downstream mediators of ANG II action. An understanding of the mechanisms underlying gender differences is obviously of great importance for the design of better strategies for prevention and treatment of cardiac disease and arrhythmias in diabetes and other cardiac pathologies.
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